Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 8/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510765 | 1.00 | GRIN2B (0.45) | GRIN2BHCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL8510018 | 0.86 | GRIN2B (0.43) | GRIN2BHCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL8510014 | 0.86 | GRIN2B (0.43) | GRIN2BHCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL8511717 | 0.79 | PDE10A (0.39) | HCRTR1HCRTR2AGTR2HRH3 | |
| SCHEMBL8511709 | 0.79 | PDE10A (0.39) | HCRTR1HCRTR2AGTR2HRH3 | |
| SCHEMBL8509517 | 0.73 | AGTR2 (0.37) | AGTR2DPP4DPP9 | |
| SCHEMBL8509515 | 0.73 | AGTR2 (0.37) | AGTR2DPP4DPP9 | |
| SCHEMBL16174466 | 0.70 | GRIN2B (0.56) | GRIN2BHCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL16174465 | 0.70 | GRIN2B (0.56) | GRIN2BHCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL16174448 | 0.70 | GRIN2B (0.53) | GRIN2BHCRTR1HCRTR2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | claimed |
| US-8865738-B2 | 5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CA9, SCN9A, CCR9 | GRIN2B 395/4885HCRTR1 236/4885HCRTR2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.